FLEX vs NBIX · P/E 23, rev $6.40B vs P/E 45, rev $2.36B
Flex Ltd (FLEX) versus Neurocrine Biosciences Inc (NBIX) — a side-by-side from cached financials, not a winner call.
Flex Ltd (FLEX) is a electronic components company listed on US.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
Latest reported FLEX revenue for 2025-03-31 was $6.40B. Net income was $838.0M. Revenue was down 2.4% from 2024-12-31 to 2025-03-31. FLEX currently screens at market cap $18.12B and trailing P/E 23.0.
Latest reported NBIX revenue for 2024-12-31 was $2.36B. Net income was $341.3M. Revenue was up 24.8% from 2023-12-31 to 2024-12-31. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
FLEX currently screens at market cap $18.12B and trailing P/E 23.0. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Not investment advice. Open the FLEX and NBIX stock pages for the full models.
Not investment advice.